Loading…
← CockpitCompetitor Analysis › 195940.KS HK inno.N CorporationOpen in the cockpit ↗

HK inno.N Corporation195940.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical/Nursing Services
Momentum strong 68
Mkt cap
$783M
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$2.67M
20-day average traded
Fwd P/E
12.3×
forward earnings
ROIC−WACC
+0.2 pp
WACC 5.4%
Hurdle
-17 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · KRW₩36,400
1D-0.6%
1W+0.4%
1M+3.9%
3M-12.6%
6M-28.1%
YTD-26.2%
1Y-30.0%
ATR %4.5%
52w lowhigh37.9% off high

What HK inno.N does

Employees: 1,723

HK inno.N at a glance

Size HK inno.N (195940.KS) is a South Korea Health Care company (Medical/Nursing Services) with a market value of $783M, the 275th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩36,400 on 18 Nov 2026.

Performance Over six months the shares fell 28.1%, against +0.9% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 7.1% over the last twelve months (peer median +4.1%); the operating margin is 11.9% (peer median 6.8%).

Valuation It trades at 12.3× forward earnings against a peer median of 19.8× (7th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -17 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.2 points above its cost of capital (5.4% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 104195940.KS 74
Six months, rebased to 100: HK inno.N against the median of its 20 peers (local-currency closes).

HK inno.N financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩1.08T₩1.06T₩897B₩829B₩847B
Revenue growth—+19%+8%-2%—
Gross profit₩480B₩472B₩414B₩355B₩333B
EBITDA₩174B₩156B₩130B₩101B₩87.1B
Net income₩86.9B₩75.7B₩61.6B₩47.2B₩38.1B
Free cash flow₩93.4B₩73.2B-₩25.9B₩32.4B₩26.7B
Capital expenditure₩47.0B₩86.3B₩126B₩39.1B₩22.9B
Total debt₩467B₩522B₩439B₩451B₩457B

Quarterly statements and history in the cockpit →

HK inno.N competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%0%+20%1951TTALOGMRSTHYROCARENEPHROPLUSFLGTWELL4694REGAHCO688315DNAGDRX301060NUTXMETROPOLISOPKPNTGDIACLARI195940.KS6-month return →1-month return →
Up and to the right = strong over both horizons. HK inno.N is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×1951TTALOGMRSTHYROCARENEPHROPLUSWELL4694REG688315GDRXNUTXMETROPOLISPNTGDIACLARI195940.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HK inno.N is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%1951TTALOGMRSTHYROCAREWELL4694GDRXNUTX195940.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HK inno.N is the large dot.

HK inno.N competitors and peer comparison

How HK inno.N compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HK inno.N against its 20 peers (data as of 18 Nov 2026)
Measure195940.KSPeer medianRank in peer set
1-month return+3.9%+1.0%6th highest of 21
6-month return-28.1%+0.9%2nd lowest of 21
Distance from 52-week high-37.9%-24.0%6th lowest of 21
Revenue growth (TTM)+7.1%+4.1%8th highest of 21
Operating margin11.9%6.8%8th highest of 21
Forward P/E12.3×19.8×7th cheapest of 16
Growth the price implies (Req g, 7 yrs)-4.7%10.1%5th least demanding of 18
Growth delivered (Del g)+12.2%+10.9%9th highest of 18
Hurdle (Req g minus delivered)-16.8 pp-1.1 pp3rd least demanding of 18
ROIC minus cost of capital+0.2 pp-0.3 pp10th highest of 20
EV / EBITDA7.8×9.2×7th cheapest of 16
Net debt / EBITDA1.9×2.0×8th least indebted of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HK inno.N 195940.KSSouth Korea$783M-28%+7%12%12.3×-4.7%+12.2%
Jinxin Fertility 1951.HKHong Kong$758M-4%+7%11%23.1×17.8%+12.4%
Terveystalo Oy TTALO.HEFinland$832M-26%-8%8%10.7×-5.1%+5.3%
GMR Solutions GMRSUnited States$714M-8%-4%14%5.9×-19.6%-4.0%
Thyrocare Technologies THYROCARE.NSIndia$858M+7%+22%26%36.0×28.5%+10.9%
Nephrocare Health Services NEPHROPLUS.NSIndia$702M+1%+33%13%48.8×36.6%+31.6%
Fulgent Genetics FLGTUnited States$702M+53%+5%-38%n/an/an/a
WELL Health Technologies WELL.TOCanada$661M-9%+29%6%10.1×10.1%+94.5%
BML 4694.TJapan$932M+12%+4%7%19.8×-9.0%+1.6%
Regis Healthcare REG.AXAustralia$962M-28%+17%4%25.3×13.3%+14.4%
AdaptHealth AHCOUnited States$1.01B-30%-3%3%n/a16.8%+25.2%
Novogene 688315.SSChina$1.01B+13%+6%7%44.8×13.9%+8.2%
Ginkgo Bioworks DNAUnited States$547M+9%-44%-242%n/an/an/a
GoodRx GDRXUnited States$1.15B+33%-2%12%10.6×6.3%+7.7%
Shanghai Labway Clinical Laboratory 301060.SZChina$518M-17%-19%6%n/a5.9%+3.2%
Nutex Health NUTXUnited States$1.19B+42%-19%39%6.5×-18.0%+253.5%
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%44.5×32.4%+10.5%
OPKO Health OPKUnited States$1.25B+37%-22%-29%n/an/an/a
Pennant PNTGUnited States$1.26B+1%+39%6%23.7×20.7%+19.4%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%19.5×7.3%+18.9%
Clariane CLARI.PAFrance$1.32B-20%+1%6%8.2×6.8%+6.5%

Questions

Which companies are HK inno.N's closest peers?
The cockpit's peer set: Jinxin Fertility (1951.HK), Terveystalo Oy (TTALO.HE), GMR Solutions (GMRS), Thyrocare Technologies (THYROCARE.NS), Nephrocare Health Services (NEPHROPLUS.NS), Fulgent Genetics (FLGT), WELL Health Technologies (WELL.TO), BML (4694.T).
Is HK inno.N expensive compared with its peers?
On forward p/e it trades at 12.3× against a peer median of 19.8×, 7th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -17 pp: the price already allows for a slowdown.
How has HK inno.N stock performed?
Over six months to 18 Nov 2026 the shares returned -28.1% against +0.9% for the median peer; over one year -30.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.